| Literature DB >> 24126111 |
Akira Tominaga1, Yuko Konishi, Takahiro Taguchi, Satoshi Fukuoka, Tokuichi Kawaguchi, Tetsuo Noda, Keiji Shimizu.
Abstract
In order to analyze the damage of human epithelial cells, we used human quasi-normal FPCK-1-1 cells derived from a colonic polyp in a patient with familial adenomatous polyposis as a monolayer, which is co-cultured with peptidoglycan (PGN)-stimulated THP-1 cells. Co-cultured FPCK-1-1 cells showed a decreased transepithelial electrical resistance (TER) and the lower level of claudin-2. When Spirulina complex polysaccharides were added one day before the start of the co-culture, there was no decrease of TER and claudin-2 (early phase damage). In contrast, when Spirulina complex polysaccharides were added to FPCK-1-1 cells after the level of TER had decreased, there was no recovery at the level of claudin-2, though the TER level recovered (late phase damage). The mucosa reconstitution is suggested to be involved in the recovery from the damaged status. Interestingly, autonomous recovery of FPCK-1-1 cells from both the early and late phase damage requires the production of IL-22, because anti-IL-22 antibodies inhibited recovery in these cases. Antibodies against either TLR2 or TLR4 inhibited the production of IL-22 from FPCK-1-1 colon epithelial cells, suggesting that signals through TLR2 and TLR4 are necessary for autonomous recovery of FPCK-1-1 colon epithelial cells by producing IL-22. In conclusion, we have established a useful model for the study of intestinal damage and recovery using human colon epithelial cells and our data suggest that damage to human colon epithelial cells can, at least in part, be recovered by the autonomous production of IL-22 in response to Spirulina complex polysaccharides.Entities:
Keywords: CPS; Colon epithelial cells; IL-22; LPS; PGN; PMA; PS; Spirulina complex polysaccharides; TLR2; TLR4; complex polysaccharides; lipopolysaccharides; peptidoglycan; phorbol 12-myristate 13-acetate, 12-o-tetradecanoylphorbol 13-acetate; polysaccharides
Mesh:
Substances:
Year: 2013 PMID: 24126111 DOI: 10.1016/j.intimp.2013.09.023
Source DB: PubMed Journal: Int Immunopharmacol ISSN: 1567-5769 Impact factor: 4.932